Drug intelligence / Profile preview

GS-6212

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

GS-6212 is a novel antiretroviral drug developed by Gilead Sciences for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection. It functions as an integrase inhibitor, a class of drugs that block the HIV enzyme integrase, which is essential for the virus to multiply. It is currently being investigated in Phase 1 clinical trials and is administered orally.

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on GS-6212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-6212.

Explore the full profile